Utah Medical Products annual revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Utah Medical Products Revenue Growth & History (UTMD)
Utah Medical Products reported $38.5M in revenue for fiscal 2025, a decrease of 5.83% from the previous fiscal year.
View full Utah Medical Products company overviewUtah Medical Products annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $38.5M | −$2.4M | −5.83% |
| 2024 | 2024-12-31 | $40.9M | −$9.3M | −18.56% |
| 2023 | 2023-12-31 | $50.2M | −$2.1M | −3.93% |
| 2022 | 2022-12-31 | $52.3M | $3.2M | +6.58% |
| 2021 | 2021-12-31 | $49.1M | $6.9M | +16.30% |
| 2020 | 2020-12-31 | $42.2M | −$4.7M | −10.08% |
| 2019 | 2019-12-31 | $46.9M | $4.9M | +11.68% |
| 2018 | 2018-12-31 | $42.0M | $584,000 | +1.41% |
| 2017 | 2017-12-31 | $41.4M | $2.1M | +5.38% |
| 2016 | 2016-12-31 | $39.3M | −$859,000 | −2.14% |
| 2015 | 2015-12-31 | $40.2M | −$1.1M | −2.72% |
| 2014 | 2014-12-31 | $41.3M | $785,000 | +1.94% |
| 2013 | 2013-12-31 | $40.5M | −$1.1M | −2.55% |
| 2012 | 2012-12-31 | $41.6M | $3.7M | +9.75% |
| 2011 | 2011-12-31 | $37.9M | $12.7M | +50.71% |
| 2010 | 2010-12-31 | $25.1M | −$795,000 | −3.07% |
| 2009 | 2009-12-31 | $25.9M | — | — |
Utah Medical Products quarterly revenue
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.5M | −$1.4M | −14.31% |
| Q1 2026 | 2026-03-31 | $8.7M | −$988,000 | −10.18% |
| Q4 2025 | 2025-12-31 | $9.0M | −$113,000 | −1.23% |
| Q3 2025 | 2025-09-30 | $9.8M | −$193,000 | −1.93% |
| Q2 2025 | 2025-06-30 | $10.0M | −$447,000 | −4.30% |
| Q1 2025 | 2025-03-31 | $9.7M | −$1.6M | −14.37% |
| Q4 2024 | 2024-12-31 | $9.2M | −$3.2M | −25.75% |
| Q3 2024 | 2024-09-30 | $10.0M | −$2.5M | −19.99% |
| Q2 2024 | 2024-06-30 | $10.4M | −$2.5M | −19.17% |
| Q1 2024 | 2024-03-31 | $11.3M | −$1.2M | −9.42% |
| Q4 2023 | 2023-12-31 | $12.3M | −$1.2M | −9.15% |
| Q3 2023 | 2023-09-30 | $12.5M | −$450,000 | −3.47% |
| Q2 2023 | 2023-06-30 | $12.9M | −$562,000 | −4.19% |
| Q1 2023 | 2023-03-31 | $12.5M | $197,000 | +1.60% |
| Q4 2022 | 2022-12-31 | $13.6M | $661,000 | +5.12% |
| Q3 2022 | 2022-09-30 | $13.0M | $383,000 | +3.05% |
| Q2 2022 | 2022-06-30 | $13.4M | $824,000 | +6.54% |
| Q1 2022 | 2022-03-31 | $12.3M | $1.4M | +12.40% |
| Q4 2021 | 2021-12-31 | $12.9M | $904,000 | +7.53% |
| Q3 2021 | 2021-09-30 | $12.6M | $2.1M | +19.97% |
| Q2 2021 | 2021-06-30 | $12.6M | $3.8M | +43.44% |
| Q1 2021 | 2021-03-31 | $11.0M | $62,000 | +0.57% |
| Q4 2020 | 2020-12-31 | $12.0M | $179,000 | +1.51% |
| Q3 2020 | 2020-09-30 | $10.5M | −$2.0M | −16.13% |
| Q2 2020 | 2020-06-30 | $8.8M | −$3.1M | −25.82% |
| Q1 2020 | 2020-03-31 | $10.9M | $170,000 | +1.58% |
| Q4 2019 | 2019-12-31 | $11.8M | $2.1M | +21.27% |
| Q3 2019 | 2019-09-30 | $12.5M | $2.1M | +20.25% |
| Q2 2019 | 2019-06-30 | $11.8M | $881,000 | +8.03% |
| Q1 2019 | 2019-03-31 | $10.7M | −$155,000 | −1.42% |
| Q4 2018 | 2018-12-31 | $9.8M | −$445,000 | −4.36% |
| Q3 2018 | 2018-09-30 | $10.4M | $265,000 | +2.62% |
| Q2 2018 | 2018-06-30 | $11.0M | $136,000 | +1.26% |
| Q1 2018 | 2018-03-31 | $10.9M | $628,000 | +6.12% |
| Q4 2017 | 2017-12-31 | $10.2M | $1.3M | +15.24% |
| Q3 2017 | 2017-09-30 | $10.1M | $470,000 | +4.87% |
| Q2 2017 | 2017-06-30 | $10.8M | $339,000 | +3.23% |
| Q1 2017 | 2017-03-31 | $10.3M | −$42,000 | −0.41% |
| Q4 2016 | 2016-12-31 | $8.9M | −$730,000 | −7.62% |
| Q3 2016 | 2016-09-30 | $9.7M | −$290,000 | −2.92% |
| Q2 2016 | 2016-06-30 | $10.5M | $93,000 | +0.89% |
| Q1 2016 | 2016-03-31 | $10.3M | $68,000 | +0.66% |
| Q4 2015 | 2015-12-31 | $9.6M | −$661,000 | −6.45% |
| Q3 2015 | 2015-09-30 | $9.9M | −$772,000 | −7.20% |
| Q2 2015 | 2015-06-30 | $10.4M | −$94,000 | −0.90% |
| Q1 2015 | 2015-03-31 | $10.2M | $406,000 | +4.13% |
| Q4 2014 | 2014-12-31 | $10.2M | $158,000 | +1.57% |
| Q3 2014 | 2014-09-30 | $10.7M | $685,000 | +6.83% |
| Q2 2014 | 2014-06-30 | $10.5M | $489,000 | +4.89% |
| Q1 2014 | 2014-03-31 | $9.8M | −$547,000 | −5.27% |
| Q4 2013 | 2013-12-31 | $10.1M | $253,000 | +2.57% |
| Q3 2013 | 2013-09-30 | $10.0M | −$457,000 | −4.36% |
| Q2 2013 | 2013-06-30 | $10.0M | −$23,000 | −0.23% |
| Q1 2013 | 2013-03-31 | $10.4M | −$832,000 | −7.42% |
| Q4 2012 | 2012-12-31 | $9.8M | −$74,000 | −0.75% |
| Q3 2012 | 2012-09-30 | $10.5M | −$295,000 | −2.74% |
| Q2 2012 | 2012-06-30 | $10.0M | −$352,000 | −3.39% |
| Q1 2012 | 2012-03-31 | $11.2M | $4.4M | +64.96% |
| Q4 2011 | 2011-12-31 | $9.9M | — | — |
| Q3 2011 | 2011-09-30 | $10.8M | $4.6M | +73.91% |
| Q2 2011 | 2011-06-30 | $10.4M | $4.1M | +65.34% |
| Q1 2011 | 2011-03-31 | $6.8M | — | — |
| Q3 2010 | 2010-09-30 | $6.2M | — | — |
| Q2 2010 | 2010-06-30 | $6.3M | — | — |
Utah Medical Products revenue growth trends
Over the last five reported fiscal years, revenue declined from $42.2M to $38.5M, a compound annual decline of 1.80%. Utah Medical Products's latest reported quarter, Q2 2026, generated $8.5M in revenue, a decrease of 14.31% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Utah Medical Products source filings ↗Community posts
Utah Medical launches $75-per-share self-tender offer
Utah Medical Products ($UTMD) commenced a tender offer to repurchase up to 650,000 common shares at $75 each. At full acceptance, the share purchase would total $48.75 million before related costs. The offer follows previously announced ter ...
